DNMT3A as a clonal hematopoiesis of undetermined potential (CHIP) mutation is not considered a high-risk mutation per the ELN 2022 leukemia classification, and it responds optimally to standard therapy with long term complete remission and cure [29]. This evidence concerns the gene DNMT3A and leukemia.